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Background: Betatrophin is a member of the angiopoietin-like (ANGPTL) family that has been implicated in 
both triglyceride and glucose metabolism. The physiological functions and molecular targets of this protein 
remain largely unknown; hence, a purified available protein would aid study of the exact role of betatrophin in 
lipid or glucose metabolism.  
Methods: In this study, we cloned the full-length cDNA of betatrophin from a human liver cDNA library. 
Betatrophin was expressed in the pET-21b-E. coli Bl21 (DE3) system and purified by immobilized metal-
affinity chromatography and ion-exchange chromatography.  
Results: Circular dichroism spectroscopy revealed α-helix as the major regular secondary structure in 
recombinant betatrophin.  
Conclusion: The production method is based on commonly available resources; therefore, it can be readily 
implemented. 




Betatrophin, also known as lipasin, TD26, 
ANGPTL8, and RIFL, is a circulating protein that 
is expressed mostly in liver and white and brown 
adipose tissue. The human betatrophin gene is 
located on chromosome 19p13.2, on the strand 
opposite of the host gene dedicator of cytokinesis 6 
(Dock6). The primary structure of betatrophin 
predicts a 198-amino-acid protein with a signal 
peptide at the N-terminus and two coiled-coil 
domains. To date, several betatrophin orthologs 
have been identified in mammals; however, there is 
no evidence of betatrophin expression in other 
species.  
Initially betatrophin was detected as a tumor-
associated antigen. In 2012, its role in control of 
serum triglyceride levels or its probable function in 
lipid metabolism was described (1, 2). Recently,
betatrophin was reported to mediate an increase in 
beta-cell proliferation in response to insulin 
resistance induced by treatment with the insulin 
antagonist S961 (3-5). However, the role of 
betatrophin in beta cell proliferation and lipid 
metabolism remains controversial (6, 7); 
particularly, recent findings appear to be in conflict 
with the Yi-et al. observations (8). Therefore, 
further studies may be necessary to determine the 
biochemical properties of this protein. The current 
study was conducted to produce a recombinant 
form of this protein in a bacterial host and evaluate 
its biophysical properties. 
 
Materials and Methods 
cDNA cloning of human betatrophin 
Primers were designed to the 5′ and 3′ ends of 
human betatrophin based on the sequence from 
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GenBank accession number NM_018687.6 The 
forward and reverse primers were: 5' 
GCCCCCATGGGCGGCCCA 3' and 5' 
GGCTGGGAGCGCCGCTGT 3', respectively. 
These primers were used to PCR amplify the 
coding sequence of betatrophin from a human 
liver QUICK-Clone™ cDNA library (Clontech 
Laboratories, USA). Not-I and Xho-I sites were 
incorporated into the primers at the 5′ and 3′ 
ends, respectively, to allow sub-cloning into the 
pET-21b bacterial expression vector (Clontech 
Laboratories, USA).  
Amplification of the betatrophin coding 
sequence 
Betatrophin DNA was amplified by PCR in a 
gradient thermal cycler (Eppendorf, Germany). 
The reaction mixture contained 200 ng of primer, 
200 μmol of dNTP mixture, 1X PCR buffer, and 
1U of ExPrime Taq DNA polymerase (GenetBio, 
Korea). Amplification conditions were as follows: 
5 min at 96 °C, followed by 35 cycles of 94 °C for 
40 sec, 61 °C for 40 sec, 72 °C for 60 sec, and a 
final extension at 72 °C for 10 minutes.  
Molecular cloning of betatrophin 
The PCR product and vectors were cut with 
restriction enzymes Not-I and Xho-I 
(Fermentase, Lithuania). The purified restricted 
PCR product was ligated into pET-21b with T4 
DNA ligase (Fermentase, Lithuania). Competent 
E. coli TOP-10 cells were transformed with the 
ligation product and the transformed cells were 
grown at 37 °C overnight on Luria-Bertani (LB) 
plates containing 100 μg/ml of ampicillin 
(Sigma-Aldrich). Plasmids were isolated from 
five positive clones using a QIAGEN plasmid 
extraction and purification kit and the insert size 
was confirmed by PCR using T7 polymerase-
specific primers (T7 Promotor primer; 
TAATACGACTCACTATAGGG and T7 
Terminator primer; 
GCTAGTTATTGCTCAGCGG). The selected 
plasmids were sequenced at the Gene-Ray 
biotechnology company. Nucleotide and 
presumed protein sequences were examined by 
the ExPASy tools 
(http://www.expasy.org/tools/). The nucleotide 
sequence was searched for homology using 
BLASTn at NCBI. 
 
Expression of recombinant betatrophin 
E. coli BL-21 (DE3) as the expression host was 
transformed with the pET-21b-betatrophin 
construct. A positive clone harboring the plasmid 
was picked and grown overnight in liquid LB 
with 100 μg/ml of ampicillin at 37°C to control 
expression of the desired protein. After reaching 
the 0.6 OD600nm, expression was induced using 
isopropyl-1-thio-β-D-galactopyranoside (IPTG). 
Optimization of expression was attempted on 5 ml 
cultures of LB at of IPTG concentrations of 0.6, 
0.8, 1, and 1.2 mM, temperatures of 18, 25, and 37 
°C, and incubation times of 8, 12, and 18 hours.  
After optimization, the E. coli cells were 
cultivated in larger volumes and the final 
suspension was centrifuged at 12000 × g at 4 °C 
for 30 min to remove the cellular debris and 
resuspended in lysis buffer containing 50 mM 
NaH2PO4, 300 mM NaCl, and 10 mM 
imidazole, and disrupted by sonication using 6 x 
10 second cycles at 200-300 W. The lysate was 
centrifuged at 12000 × g for 30 min at 4 °C and 
aliquots from the supernatant and pellet were 
used to determine recombinant protein 
expression by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) 
and Coomassie brilliant blue staining. The 
inclusion bodies were separated and solubilized 
using denaturing lysis buffer containing 100 mM 
NaH2PO4, 10 mM Tris-HCl, and 6 M urea (9). 
 
Purification of recombinant betatrophin 
The solubilized fraction was dialyzed against 
binding buffer containing 0.15 M NaCl, 10% 
glycerol, 0.5% Triton X-100, and 50 mM 
sodium phosphate, pH 7.8, for 18 h at 4 °C and 
filtered through a 0.22 μm polyvinylidene 
fluoride (PVDF) membrane. Three hundred µl of 
the dialyzed fraction were loaded onto a Ni-IDA 
resin column (Parstous Co.). The protein was 
eluted using the recommended buffer containing 
0.15 M NaCl, 50 mM sodium phosphate, and 0.5 
M imidazole, pH 7.8, at a 0.5 ml/min flow rate. 
The eluted fractions were collected in 1 ml 
volumes. 
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Fraction purity was examined by 
electrophoresis on 15% SDS-PAGE using 10 μl 
of each purified fraction per lane. The protein 
bands were visualized with 0.05% Coomassie 
brilliant blue G-250. The protein content was 
measured by the Lowry method using bovine 
serum albumin (BSA) as the standard (10).  
The recombinant protein from the metal 
affinity-purified fractions was cleared using ion-
exchange chromatography. Proteins were 
resolved by an AKTA prime plus fast protein 
liquid chromatography (FPLC) system (GE 
Healthcare, Life Science, USA) using 
diethylaminoethyl (DEAE) sepharose 6B resin 
(Pharmacia, Uppsala, Sweden) to remove all 
impurities, especially bacterial 
lipopolysaccharides.  
The betatrophin-rich fraction was dialyzed 
against starting buffer containing 20 mM Tris-
HCl, pH 8.6, for 18 h at 4 °C and filtered through 
a 0.22 μm PVDF membrane. Approximately 10 
ml of resin was packed into an adjustable column 
and equilibrated with the same starting buffer. 
Five hundred μl of the dialyzed extract were 
loaded onto the column. Proteins were eluted 
with the starting buffer containing a linear 
gradient of NaCl at a constant rate of 0.75 
ml/min. The eluent was monitored at 280 nm 
and results were recorded.  
 
Circular dichroism (CD) spectroscopy  
The recombinant betatrophin was examined in 
the far ultraviolet (UV) region of 190-240 nm, 
which corresponds to peptide bond absorption, 
using an AVIV model J810 spectropolarimeter 
(JASCO) to give the content of regular 
secondary structures. Far UV-CD spectra of a 40 
μg/ml solution of purified proteins in PBS buffer, 
pH 6.5, were obtained with a 1 mm path length 
quartz cell. The background was corrected 
against the buffer blank. The data were 
calculated as molar ellipticity (deg.cm2/dmol) 
assuming a mean residue number and average 
molecular weight of 27.5 kDa for betatrophin 
using the CD deconvolution software. The molar 
ellipticity was determined as [θ] = [100 × 
(MRW) × θobs/(cl), where θobs is the observed 
ellipticity in degrees at a given wavelength and c 
is the light path length in cm (11). 
 
Results 
The human betatrophin gene was amplified from a 
cDNA library with 5′ and 3′ cloning primers. A 
single PCR product of 531 bp was obtained (Fig. 1) 
and cloned into pET-21b. The recombinant plasmid 
was confirmed by gene sequencing. The results 
verified that the betatrophin insert was subcloned 
into pET-21b and the expression vector was 
constructed successfully. Also, the nucleotide 
sequence of the cloned fragment displayed 100% 
identity with the betatrophin nucleotide sequence 
in GenBank: KF809856.1.  
 
 
Fig. 1. Agarose gel electrophoresis of betatrophin PCR 
products obtained from a human cDNA library. Lane 1, 
DNA 10 kbp ladder, Lanes 2 and 3, 531 bp PCR products.  
 
The E. coli BL-21 cells transformed with the 
construct were grown in LB media at 37 °C until 
OD reached 0.6; then protein expression was 
induced with IPTG overnight. The optimal IPTG 
concentration for protein induction was 1 mM 
(Fig. 2). The expression at 1 mM IPTG was also 
corroborated in the time course experiments. 
Finally, the influence of temperature on 
betatrophin expression was tested at 18, 25, and 
37 °C. The highest-yield expression was reached 
at 37 °C for 12 hours. 
The results indicated that the optimal condition 
for the expression of the construct in LB media 
was at 37 °C with 1 mM IPTG for 12 hours. 
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Assessment of protein expression in the 
soluble and insoluble cell lysate fractions 
revealed that a significant amount of protein 
distributed into the insoluble fraction. As 
indicated in the SDS-PAGE, a distinct band with 
considerable intensity was present in the 
insoluble fraction following treatment with 6 M 




Fig. 2. SDS-PAGE of recombinant betatrophin expressed at 
different IPTG concentrations. Lane 1; Protein molecular 
weight marker, Lane 2; 0.6 mM IPTG, Lane 3; 0.8 mM 
IPTG, Lane 4; 1 mM IPTG, Lane 5; 1.2 mM IPTG. (The 
expression without IPTG was low, data not shown)  
 
 
The recombinant human betatrophin was 
purified by metal-chelate and ion-exchange 
chromatography. The purification yield was 3 
mg/L of culture in Ni-IDA chromatography and 
2 mg/L of culture in ion-exchange (Fig. 4A), 
indicating that a considerable amount of protein 
was lost during the clarification steps.   
 
 
Fig. 3. Purification of recombinant betatrophin A. SDS-
PAGE of recombinant betatrophin. In each case, following cell 
lysis and centrifugation, the cell pellet was isolated and 
extracted with urea (see methods for details). Lane 1; 
Molecular weight standard, Lane 2; Cell pellet following the 
centrifugation of urea-treated-cell extracts, Lane 3; Supernatant 
following the centrifugation of urea-treated cell extracts.  
B. SDS-PAGE of recombinant betatrophin after Ni-IDA 
chromatography. Lane 1; Molecular weight standard, Lane 2; 








The SDS-PAGE of protein fractions obtained 
from the chromatography showed a single 
protein band of 27.5 kDa, the expected 
molecular mass for the recombinant protein 
based on the estimated molecular mass of human 
betatrophin of 22 kDa, the 6-His tag of 2.7 kDa, 
and 2.8 kDa from other amino acids encoded in 
the plasmid (Fig. 3B). 
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The results of the CD analysis of the 
recombinant betatrophin are shown in Fig. 4B 
and Table 1. The main regular secondary 
structure found in recombinant betatrophin was 
α-helix. Notably, no β-sheet structure was 
revealed for recombinant betatrophin. 
Table 1. Percentages of secondary structures in betatrophin 
Secondary structures 
 
Random Coil β-Turn β-Sheet α-Helix 
33.2 26.2 0.0 40.7 Percentage of the structure 
 
Discussion 
Betatrophin is a novel liver-secreted protein with 
yet unknown function and mechanism. 
Betatrophin was originally reported to be 
associated with the control of beta cell 
proliferation (3). It was reported that betatrophin 
controls beta cell proliferation in mice treated 
with the insulin receptor antagonist S961.The 
direct or indirect mechanism of action for 
betatrophin has not been described; however, it is 
clear that betatrophin is not obligatory for beta 
cell function or compensation of beta cell growth 
response to insulin antagonist receptors (12, 13). 
Furthermore, betatrophin overexpression does 
not increase beta cell proliferation or blood 
glucose levels (14). Zhang et al. indicated that 
betatrophin inhibits lipoprotein lipase (LPL) 
activity and may control serum triglyceride level 
(15). Their study also showed that betatrophin 
level was nutritionally regulated.  
Generally, many aspects of betatrophin function 
are unknown and in some cases are controversial. 
To understand betatrophin’s structure and function, 
pure protein in adequate quantities for detailed 
biochemical and biophysical studies is needed. 
Thus, a straightforward procedure for production of 
recombinant protein with high yield would be 
valuable. Therefore, we tried to simplify the human 
betatrophin cloning, expression, and purification 
process by cloning the gene in the pET system. 
However, because the structure of most human 
proteins is relatively complex, their functional 
recombinant forms may be better expressed in 
eukaryotic systems (16). 
In this study, the optimized condition for 
expression of recombinant betatrophin was found 
to be at 37 °C with 1 mM IPTG. These
 
 
expressions conditions are similar to those found 
in other reports of recombinant protein expression 
in bacterial hosts, however, we found no data on 
betatrophin cloning or expression conditions.  
In this study CD spectroscopy was used to 
determine the secondary structures in recombinant 
betatrophin. We found that the recombinant 
betatrophin consists of 40.7% α-helix, 26.2% β-
turn, and 33.2% random coil, which agreed with 
the predicted secondary structure obtained by the 
Network Protein Sequence Analysis tool (data not 
shown) (17). We found no published data on 
betatrophin structure. 
In conclusion, in this study, the human 
betatrophin gene was amplified by conventional 
PCR from a human cDNA library and cloned into 
pET-21b. The recombinant protein was expressed 
in BL21 (DE3) cells, and purified and clarified by 
metal affinity and anion exchange 
chromatography, respectively. Circular dichroism 
revealed that the major secondary structure in 
recombinant betatrophin is α-helix. The production 
procedure is easy to implement, which allows the 
production of large quantities of recombinant 
protein with no need for special equipment or 
media. Hence, more studies on betatrophin 
structure and function could be designed to 
determine of its effects on beta cell proliferation 
and triglyceride levels. 
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